These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17368861)

  • 1. Why invest in a national public health program for stroke? An example using Australian data to estimate the potential benefits and cost implications.
    Cadilhac DA; Carter RC; Thrift AG; Dewey HM
    Health Policy; 2007 Oct; 83(2-3):287-94. PubMed ID: 17368861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organized blood pressure control programs to prevent stroke in Australia: would they be cost-effective?
    Cadilhac DA; Carter R; Thrift AG; Dewey HM
    Stroke; 2012 May; 43(5):1370-5. PubMed ID: 22363058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
    Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
    Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event.
    Tavakoli M; Pumford N; Woodward M; Doney A; Chalmers J; MacMahon S; Macwalter R
    Eur J Health Econ; 2009 Feb; 10(1):111-9. PubMed ID: 18446392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of Australia's Active After-School Communities program.
    Moodie ML; Carter RC; Swinburn BA; Haby MM
    Obesity (Silver Spring); 2010 Aug; 18(8):1585-92. PubMed ID: 19893504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifetime direct costs of stroke for indigenous patients adjusted for comorbidities.
    Zhao Y; Condon J; Lawton P; He V; Cadilhac DA
    Neurology; 2016 Aug; 87(5):458-65. PubMed ID: 27371489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia.
    Haji Ali Afzali H; Gray J; Beilby J; Holton C; Karnon J
    Appl Health Econ Health Policy; 2013 Dec; 11(6):661-70. PubMed ID: 24243516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of skin cancer prevention in Australia.
    Shih ST; Carter R; Sinclair C; Mihalopoulos C; Vos T
    Prev Med; 2009 Nov; 49(5):449-53. PubMed ID: 19747936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status and costs of primary prevention for ischemic stroke in China.
    Zhao JJ; He GQ; Gong SY; He L
    J Clin Neurosci; 2013 Oct; 20(10):1427-32. PubMed ID: 23938016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Burden and Cost-Effective Analysis of the Nationwide Implementation of the Quality in Acute Stroke Care Protocol in Australia.
    Marquina C; Ademi Z; Zomer E; Ofori-Asenso R; Tate R; Liew D
    J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105931. PubMed ID: 34157669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of extending the coverage of water supply fluoridation for the prevention of dental caries in Australia.
    Cobiac LJ; Vos T
    Community Dent Oral Epidemiol; 2012 Aug; 40(4):369-76. PubMed ID: 22452320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
    Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
    Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing costs and potential returns of evidence-based programs for seniors.
    Miller TR; Dickerson JB; Smith ML; Ory MG
    Eval Health Prof; 2011 Jun; 34(2):201-25. PubMed ID: 21196430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neurological complex treatment: impact on mortality in the first year and costs for statutory health insurance].
    Heumüller S; Stausberg J; Jöckel KH
    Fortschr Neurol Psychiatr; 2012 Oct; 80(10):593-8. PubMed ID: 23033204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.